cTAPcTAPcTAPcTAP
  • WHAT WE DO
  • WHO WE ARE
  • HOW WE DO IT
  • NEWS
  • CONTACT
  • IS cTAP FOR YOU?
    • Biopharmaceutical Companies
    • Scientific Leaders & Researchers
    • Patient Organizations

WMS 2018 Abstract – Minimal detectable change in NSAA

WMS 2018 Abstract – Minimal detectable change in NSAA

Minimal detectable change in the North Star Ambulatory Assessment (NSAA) in Duchenne muscular dystrophy (DMD)

View the Full PDF

03
Oct 2018
Abstracts

Read the latest

  • Prognostic factors for loss of ability to rise from supine in DMD
  • Suitability of external controls for drug evaluation in Duchenne muscular dystrophy
  • cTAP Study Shows Real-World, Natural History Data Comparable to Placebo Data from Clinical Trials in Duchenne Muscular Dystrophy
  • A prognostic model for 1 year change in 4SC
  • Deflazacort vs prednisone treatment for Duchenne muscular dystrophy

COLLABORATIVE TRAJECTORY
ANALYSIS PROJECT

Cambridge Innovative Center
One Broadway, Cambridge, MA 02142

T: 617-555-5555
E: info@ctap-duchenne.org

© 2021 Collaborative Trajectory Analysis Project. All rights reserved.

  • WHAT WE DO
  • WHO WE ARE
  • HOW WE DO IT
  • NEWS
  • CONTACT
  • IS cTAP FOR YOU?
    • Biopharmaceutical Companies
    • Scientific Leaders & Researchers
    • Patient Organizations